We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biosyent Inc | TSXV:RX | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -0.46% | 8.65 | 8.50 | 8.70 | 8.80 | 8.65 | 8.75 | 9,142 | 20:59:32 |
BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of its unique new oral iron supplement - FeraMAX(R) Powder. FeraMAX(R) Powder is the first innovation in the pediatric oral iron market in Canada in almost 50 years. The Canadian market launch will be the global introduction of this new product and provides BioSyent Pharma with a unique offering for international marketing partners. FeraMAX(R) Powder joins FeraMAX(R) 150 in providing healthcare professionals and their patients with a safe, effective, and well tolerated oral iron supplement. It is indicated for the prevention of iron deficiency and iron deficiency anaemia in newborns, infants, children and adults. FeraMAX(R) Powder is the only oral iron product available in a dissolvable powder and comes in pleasant tasting grape/raspberry flavoured gluten and alcohol-free crystals which can be conveniently dosed by diluting in water or mixing with soft foods. This innovative new product is based upon the same doctor recommended, proprietary, non-ionic polysaccharide-iron complex technology found in FeraMAX(R) 150. Other oral iron products intended for infants and children either have an unpleasant heavy metallic taste which deter patient compliance or they come in formulations containing alcohol which healthcare professionals and caregivers prefer to avoid. In addition to its clear advantages in the pediatric market, FeraMAX(R) Powder is also well suited for adult patients that have difficulty swallowing pills. FeraMAX(R) Powder was exhibited at the recent Primary Care Today medical conference attended by over 3,000 healthcare professionals. Listings have been secured at major wholesalers and shipments of FeraMAX(R) Powder, to over 30 wholesale distribution centres supplying pharmacies across Canada, will commence over the next week. "The launch of FeraMAX(R) Powder further strenghtens BioSyent Pharma's leadership position in providing innovative iron supplement solutions for healthcare professionals and their patients" said Rene Goehrum, President and CEO of BioSyent. "We now have a full range of solutions and dosing options available for all iron deficient and iron deficient anaemia patients". For more information regarding FeraMAX(R) Powder and FeraMAX(R) 150, visit www.feramax.com About BioSyent Inc. Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada. At the date of this press release the Company had 13,571,195 shares issued and outstanding. This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. FOR FURTHER INFORMATION PLEASE CONTACT: BioSyent Inc. Mr. Rene C. Goehrum President and CEO (905) 206-0013 investors@biosyent.com www.biosyent.com
1 Year Biosyent Chart |
1 Month Biosyent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions